Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Twitter Feed
-
Not all patients experience psoriasis and atopic dermatitis in the same way. A new collaboration aims to find out why. https://t.co/L4ZRU7hbBK https://t.co/XfgGLgaimK
— UCB News (@ucb_news) 24.04.2019 -
UCB is on IMI’s Steering Committee and one of 34 public and private organisations collaborating to make #patientengagement the norm https://t.co/s8vpvGhaKd @imi_paradigm https://t.co/QrDzbhsiAt
— UCB News (@ucb_news) 24.04.2019 -
It is UCB’s goal to develop and produce medicines for people with severe diseases in the most environmentally sustainable way possible. Interested in learning how we do this? ✅Check out our UCB Integrated Annual Report 2018. https://t.co/HdntLyAAbQ ht
— UCB News (@ucb_news) 16.04.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
